Browsing by Author "Nalbant, OAK"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Glomus Tumor of the Stomach: Case Report
    Nalbant, OAK; Temiz, P; Vural, S; Keles, MC
    Glomus tumors are benign, solitary neoplasms originating from modified smooth muscle cells of the glomus body. These tumors are rare in the gastrointestinal system. We present a glomus tumor that arose in the antrum of a 43-year-old female. During laparoscopic cholecystectomy for cholelithiasis, an antral submucosal tumor was found incidentally and total excision with wedge resection was performed. Histopathological and immunohistochemical features of this tumor were similar to those of a glomus tumor in any localization. In this report, we discuss the differential diagnosis of gastric glomus tumor.
  • No Thumbnail Available
    Item
    Splenic Hamartoma
    Nalbant, OAK; Nese, N; Kahya, M; Isisag, A
    Splenic hamartoma is a rare, benign lesion of the spleen requiring differential diagnosis. A 60-year-old male patient referred to the hospital with epigastric pain. Abdominal computed tomography revealed a mass in the spleen and multiple lymphadenopathies at the posterior wall of the stomach. The patient underwent splenectomy for diagnostic purposes. A pink to red, solid, well circumscribed tumoral lesion with a greatest diameter of 4.5 cm was observed on the cut surface of the splenectomy specimen in addition to ten other, not well circumscribed, dark red, solid tumoral lesions measuring between 0,3-1 cm in greatest diameter. All of the lesions were diagnosed as splenic hamartoma. As splenic hamartoma is a rare lesion and needs to be di + erentiated from other benign tumoral lesions of the spleen, this case is found worth to be presented.
  • No Thumbnail Available
    Item
    The Role of Immunohistochemistry in Differential Diagnosis of Follicular Patterned Lesions of Thyroid
    Yegen, G; Demir, MA; Ertan, Y; Nalbant, OAK; Tunçyürek, M
    Objective: In the present study we aimed to assess the role of galectin3, cytokeratin 19, thyroid peroxidase and CD44v6 in distinguishing benign from malignant follicular lesions. Material and Method: Fifty-four malignant and 50 benign lesions were evaluated and classified according to World Health Organization 2004 histological classification. Galectin-3, cytokeratin 19, thyroid peroxidase and CD44v6 were performed immunohistochemically and the slides were evaluated by two independent investigators. Sensitivity, specificity and diagnostic accuracy were assessed for each antibody tested. Results: Sensitivity, specificity and diagnostic accuracy were as follows respectively: Galectin-3: 59,25%, 84% and 71,15%; Cytokeratin 19: 70%, 82% and 75,4%; Thyroid peroxidase: 61%, 70% and 65,4%; CD44v6: 20,4%, 88% and 52,9%. Conclusion: The negativity for Galectin-3 and Cytokeratin 19 can not exclude malignancy but positivity can be thought as a sign of malignant feature or potential for lesions in which there is strong suspect of malignancy. Thyroid peroxidase immunostaining failed to differantiate benign from malignant oxyphilic tumors but decreased expression can be used as a malignancy marker together with Galectin-3 and/or Cytokeratin19 positivity in suspicious cases. CD44v6 does not seem to be reliable in distinguishing benign from malignant follicular patterned thyroid lesions. In conclusion, our approach is to take as much new samples or serial sections as possible in cases without clear-cut evidence of malignancy but with histological and immunohistochemical suspicion. Follicular variant papillary carcinoma has different criteria for malignancy and it should be always kept in mind while evaluating a benign-looking lesion with immunohistochemical signs that favor malignancy.